US Pharma MarketingThe post Kolon TissueGene’s stock drops on Phase III knee osteoarthritis trial failure appeared first on Clinical Trials Arena.
Kolon TissueGene’s stock drops on Phase III knee osteoarthritis trial failure
Kolon TissueGene’s stock dropped nearly 30% after the Phase III knee osteoarthritis trial failure. The post Kolon TissueGene’s stock drops on Phase III knee osteoarthritis trial failure appeared first on Clinical Trials Arena .
Kolon TissueGene’s stock dropped nearly 30% after the Phase III knee osteoarthritis trial failure.
Source: Clinical Trials Arena